重要的消息有哪些 1月23日（周五）申购提示 世盟股份申购代码为001220，发行价28.00元/股，申购上限0.9万股。 投资有风险，申购需谨慎。 1.中国人民银行党委书记、行长潘功胜接受访问表示，2026年，中国人民银行将继续实施好适度宽松的货币政策，把促进经济稳定增长、物价 合理回升作为货币政策的重要考量，发挥增量政策和存量政策集成效应，为经济稳定增长、高质量发展和金融市场稳定运行营造良好的货币金融 环境，为实现"十五五"良好开局提供有力的金融支撑。总量政策方面，灵活高效运用降准降息等多种货币政策工具，保持流动性充裕，使社会 融资规模、货币供应量增长同经济增长、价格总水平预期目标相匹配。今年降准降息还有一定的空间。 2.为保持银行体系流动性充裕，2026年1月23日，中国人民银行将以固定数量、利率招标、多重价位中标方式开展9000亿元MLF操作，期限为 1年期。 3.为切实维护消费者合法权益，促进产业高质量发展，国务院食安办组织国家卫生健康委、市场监管总局等部门起草了《食品安全国家标准 预 制菜》《预制菜术语和分类》草案；会同市场监管总局、商务部等部门起草了关于推广餐饮环节菜品加工制作方式自主明示的公告 ...

Group 1: Company Fundraising and Investment - Company plans to use 500 million yuan of raised funds to increase capital in its wholly-owned subsidiaries for the implementation of a DRAM investment project [1] - Zhuhai Hengqin Chip Storage Co., Ltd. will receive 30 million yuan, and Hefei Chip Storage Co., Ltd. and Xi'an Chip Storage Co., Ltd. will receive 50 million yuan and 30 million yuan respectively for the DRAM project [1] Group 2: Profit Forecasts and Turnarounds - Yiling Pharmaceutical expects a net profit of 1.2 billion to 1.3 billion yuan in 2025, recovering from a loss of 725 million yuan in the previous year [2] - Liard anticipates a net profit of 300 million to 380 million yuan in 2025, compared to a loss of 889 million yuan last year, driven by a new strategic cycle focusing on AI [2] - Daming City forecasts a net profit of 140 million to 165 million yuan in 2025, recovering from a loss in the previous year, aided by reduced asset impairment losses [3] - Guanghua Technology expects a net profit of 85 million to 120 million yuan in 2025, recovering from a loss of 205 million yuan last year, due to expansion in specialized chemicals and PCB sectors [3] - Boteng Co. anticipates a net profit of 80 million to 105 million yuan in 2025, recovering from a loss of 288 million yuan, supported by operational efficiency improvements [4] - Shiyida expects a net profit of 31 million to 46 million yuan in 2025, recovering from a loss of 2.34 million yuan last year, driven by business development and cost control [4] - Guochuang High-tech forecasts a net profit of 16 million to 24 million yuan in 2025, recovering from a loss of 49 million yuan, aided by improved receivables management [5][6] Group 3: Share Buybacks - Hengyi Petrochemical plans to repurchase shares with a total fund of no less than 500 million yuan and no more than 1 billion yuan, with a maximum price of 15 yuan per share [7] - Yunyi Electric plans to repurchase shares with a total fund of no less than 100 million yuan and no more than 150 million yuan, with a maximum price of 17 yuan per share [7] - Xidian Pharmaceutical intends to repurchase shares with a total fund of no less than 25 million yuan and no more than 50 million yuan, with a maximum price of 42 yuan per share [7] Group 4: Performance Highlights - Te Yi Pharmaceutical expects a net profit of 70 million to 90 million yuan in 2025, a growth of 241.55% to 339.13% year-on-year [8] - Xingqi Eye Medicine anticipates a net profit of 662 million to 749 million yuan in 2025, a growth of 95.82% to 121.56% year-on-year [8] - Tianhe Co. forecasts a net profit of 41 million to 60 million yuan in 2025, a growth of 84.35% to 169.78% year-on-year [8] - Ruichuang Micro-Nano expects a net profit of approximately 1.1 billion yuan in 2025, a 93% increase year-on-year [9] - Zhongyuan Co. anticipates a net profit of 139 million to 158 million yuan in 2025, a growth of 80% to 105% year-on-year [9] Group 5: Important Corporate Developments - Aolaide has received acceptance for its application to issue securities on the Science and Technology Innovation Board [14] - *ST Songfa's subsidiary signed contracts for the construction of two VLCC super-large oil tankers, expected to positively impact future performance [15] - Chongda Technology's subsidiary signed an investment agreement for a 1 billion yuan IC packaging project in Jiangsu Province [15] - Yinglian Co. signed a strategic agreement with LG Chem to establish a joint laboratory for innovative materials in lithium battery applications [16]

Core Viewpoint - The company Shiyida (002137.SZ) has announced its earnings forecast for the year 2025, projecting a net profit attributable to shareholders of between 31 million and 46 million yuan, indicating a turnaround from losses to profits [1] Financial Performance - The net profit after deducting non-recurring gains and losses is expected to be between 20 million and 30 million yuan, representing a year-on-year growth of 78.16% to 167.24% [1]

Group 1 - Huakang Clean announced it is the first candidate for the bid of the Wuhan First Hospital expansion project with a bid amount of 54.88 million yuan and a construction period of 120 days [1] - Hualing Steel's subsidiary plans to invest 449.88 million yuan in a major overhaul project for its coking plant, aiming to address aging issues and restore production capacity over a 19-month construction period [2] - Yinjia Technology expects a net loss of 140 million to 110 million yuan for 2025, compared to a loss of 129 million yuan in the previous year [3] Group 2 - Guochuang High-tech forecasts a net profit of 16 million to 24 million yuan for 2025, recovering from a loss of 58.52 million yuan in the previous year [4] - Shiyi Da anticipates a net profit increase of 31 million to 46 million yuan for 2025, turning around from a loss of 23.41 million yuan last year [5] - Lijun Co. expects a net profit of 48 million to 66 million yuan for 2025, representing a decline of 45.05% to 60.03% compared to the previous year [7] Group 3 - Xindian Pharmaceutical plans to repurchase shares worth 25 million to 50 million yuan for employee stock ownership plans or equity incentives, with a maximum repurchase price of 42 yuan per share [6] - Jingchen Co. has set the initial transfer price for its shares at 82.85 yuan per share, with a total of 13.1 million shares to be transferred to 28 institutional investors [8] - Zejing Pharmaceutical received approval for clinical trials of its innovative cancer immunotherapy drug ZG005 in combination with platinum-based chemotherapy for advanced nasopharyngeal and esophageal squamous cell carcinoma [9] Group 4 - Xingqi Eye Medicine expects a net profit of 662 million to 749 million yuan for 2025, marking a growth of 95.82% to 121.56% compared to the previous year [10] - Liancheng Precision anticipates a net loss of 12 million to 17 million yuan for 2025, reducing its loss from 37.96 million yuan in the previous year [11] - Beidou Star expects a net loss of 230 million to 290 million yuan for 2025, improving from a loss of 350 million yuan last year [13] Group 5 - Qing Shan Paper's affiliate won a bid for a wastewater treatment project worth 51.9 million yuan [15] - Yiling Pharmaceutical forecasts a net profit of 1.2 billion to 1.3 billion yuan for 2025, recovering from a loss of 725 million yuan in the previous year [16] - Huahai Pharmaceutical received a drug registration certificate for its product used in treating depression and obsessive-compulsive disorder [23] Group 6 - Nanjing Panda expects a net profit of 10 million to 15 million yuan for 2025, turning around from a loss of 189 million yuan last year [40] - Rui Sheng Intelligent anticipates a net profit of 33.92 million to 38.40 million yuan for 2025, representing a growth of 112% to 140% compared to the previous year [41] - Jiechang Drive expects a net profit of 395 million to 437 million yuan for 2025, with a growth of 40% to 55% compared to the previous year [43]

Core Viewpoint - The company Shiyida (002137) expects a significant turnaround in its financial performance, projecting a net profit attributable to shareholders of 31 to 46 million yuan for 2025, compared to a loss of 23.41 million yuan in the same period last year [1]. Group 1 - The company is focusing on its core business development and steadily advancing various business operations [1]. - The company is actively expanding both domestic and international markets [1]. - The company is implementing cost-saving measures and efficiency improvements to provide more value-added services to customers [1].

Core Viewpoint - The company expects significant growth in net profit for the year 2025, with projections indicating an increase of 232.44% to 296.52% compared to the previous year [1] Financial Performance - The estimated net profit attributable to shareholders for 2025 is projected to be between 31 million and 46 million yuan [1] - The estimated net profit after deducting non-recurring gains and losses is expected to be between 20 million and 30 million yuan, reflecting a year-on-year increase of 78.16% to 167.24% [1] Business Strategy - The company has focused on its core business development, steadily advancing various operations, and actively exploring domestic and international markets [1] - Efforts to enhance efficiency and reduce costs have been implemented, allowing the company to provide more value-added services to customers [1] Non-recurring Gains and Losses - The increase in non-recurring gains and losses is attributed to a significant loss from the fair value change of an associate company in the previous year, amounting to 49.735 million yuan [1] - The overall impact of fair value changes from associate companies on profits during the current reporting period is expected to be minimal [1]

Core Viewpoint - The company expects to achieve a net profit attributable to shareholders of 31 million to 46 million yuan in 2025, marking a turnaround from losses, with a significant increase in net profit excluding non-recurring gains and losses [1] Financial Performance - The projected net profit for 2025 is expected to grow by 232.44% to 296.52% compared to the same period last year [1] - The net profit excluding non-recurring gains and losses is anticipated to be between 20 million and 30 million yuan, reflecting a year-on-year growth of 78.16% to 167.24% [1] Strategic Focus - The company is focusing on its core business development and steadily advancing various business operations [1] - Efforts to expand both domestic and international markets are being actively pursued [1] - The company is implementing cost-saving measures and enhancing efficiency to provide more value-added services to customers [1]

Core Viewpoint - The company expects a significant turnaround in its financial performance for the fiscal year 2025, projecting a net profit attributable to shareholders between 31 million and 46 million yuan, marking a substantial increase compared to a loss of 23.41 million yuan in the previous year, representing a growth of 232.44% to 296.52% [1] Financial Performance - The anticipated net profit for 2025 is projected to be between 31 million and 46 million yuan, indicating a strong recovery from the previous year's loss [1] - The expected net profit after deducting non-recurring items is estimated to be between 20 million and 30 million yuan, reflecting a year-on-year growth of 78.16% to 167.24% [1] Factors Contributing to Growth - The company's performance improvement is attributed to a focus on its core business, market expansion, and cost reduction efforts [1] - An increase in non-recurring gains during the current period has also contributed to the anticipated financial results [1]

Financial Projections - The company expects a net profit of between 31 million and 46 million yuan for the year 2025, representing a growth of 232.44% to 296.52% compared to the same period last year[5]. - The net profit after deducting non-recurring gains and losses is projected to be between 20 million and 30 million yuan, indicating a growth of 78.16% to 167.24% year-over-year[5]. - Basic earnings per share are estimated to be between 0.0537 yuan and 0.0797 yuan, compared to a loss of 0.0405 yuan in the previous year[5]. Business Strategy - The increase in profit is attributed to the company's focus on core business development and efforts to expand both domestic and international markets[7]. - The company has implemented cost-saving measures and efficiency improvements, contributing to the growth in main business revenue and net profit[8]. Non-Recurring Items - Non-recurring gains and losses are expected to have a smaller impact on profits this period compared to the previous year, where a loss of 49.735 million yuan was recorded due to fair value changes of an associate[8]. Reporting and Auditing - The financial data presented in the earnings forecast has not been audited by an accounting firm and is based on preliminary estimates[6]. - The company advises investors to refer to the official 2025 annual report for the final operating results[9]. - The earnings forecast period is from January 1, 2025, to December 31, 2025[3]. - The announcement was made by the company's board of directors on January 23, 2026[11].

证券代码：002137 证券简称：实益达 公告编号：2026-001 深圳市实益达科技股份有限公司 关于使用自有闲置资金进行现金管理的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 深圳市实益达科技股份有限公司（以下简称"公司"）于2025年8月15日召 开了第七届董事会第十一次会议审议通过了《关于使用部分自有闲置资金进行现 金管理的议案》，并于2025年9月4日召开2025年第二次临时股东会审议通过该议 案，为提高公司自有资金使用效率，在不影响公司正常经营及业务发展的情况下， 为进一步拓宽资金投资渠道，增加投资收益，同意公司任一时点使用部分自有闲 置资金最高不超过人民币100,000万元进行现金管理，有效期为股东会审议通过 之日起12个月；资金可在上述额度内滚动使用，在额度范围内由董事会授权公司 董事长行使该项投资决策权并签署相关合同，具体投资活动由公司及子公司财务 负责人组织实施。具体内容详见公司刊登于2025年8月19日《证券时报》及巨潮 资讯网(www.cninfo.com.cn)的《关于使用部分自有闲置资金进行现金管理的公 告》。 现将公司近期使 ...